Drug price review board bill
Executive Summary
HR 1434, introduced by Rep. Durbin (D-Ill.) March 23, would establish a board, modeled on the Canadian price review board, that would collect pricing information and R&D, marketing and manufacturing costs, publish its findings, and give the board power to revoke a drug's patent if the price is found excessive. Durbin wants his proposal or a similar concept included in Clinton's health care package. The bill, which currently has four sponsors, was referred to the Energy & Commerce Committee.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth